"We have therefore retained CB Capital Partners as our financial advisor to assist in reviewing our strategic alternatives with the objective of maximizing shareholder value, and we look forward to working with them to ensure that all alternatives available to the Company are considered and evaluated to achieve that objective."
These alternatives may range from strategic alliances to assist in the development of its pipeline drugs to financing opportunities such as mergers, acquisitions, a sale of all or part of the business, or other initiatives considered to be in the best interests of the Company and its shareholders.
ABOUT CB CAPITAL PARTNERS
CB Capital Partners is a specialized investment banking firm, which focuses on creating value through customized financial advisory assignments including capital raises, debt placements, strategic and financial partnerships, and mergers and acquisitions transactions. The firm was founded in 2001 in order to bring innovative and value-added solutions to our clientele through a conservative and disciplined application of our diverse professional institutional investment banking talents. http://www.cbcapital.com
ABOUT SINOBIOMED, INC.
Sinobiomed, Inc. is a leading Chinese developer of genetically
engineered recombinant protein drugs and vaccines. Based in Shanghai,
Sinobiomed currently has 10 products approved or in development: three on
the market, four in clinical trials and three in research and development.
The Company's products respond to a wide range of diseases and conditions,
including: malaria, h
|SOURCE Sinobiomed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved